IgG4-related ophthalmic disease

Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022

Retrieved on: 
Wednesday, February 16, 2022
Private Securities Litigation Reform Act, Patient, Oyster Point, ID, Science, Forward-looking statement, U.S. Securities and Exchange Commission, IgG4-related ophthalmic disease, Security (finance), International, Nasdaq, Safety, Risk, LinkedIn, Twitter, NDA, Research, Toys "R" Us Canada, GLOBE, Pharmaceutical industry

The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time.

Key Points: 
  • The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time.
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.
  • 2022 Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 4, 2022
Oyster Point, Research, Patient, IgG4-related ophthalmic disease, Science, Twitter, LinkedIn, FDA, Board, Duane syndrome, GLOBE, Nasdaq, Financial compensation, Pharmaceutical industry

Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Key Points: 
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA(varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.
  • Oyster Point Pharma is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them.

Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

Retrieved on: 
Tuesday, December 21, 2021
Conference, Duane syndrome, Nasdaq, Patient, LinkedIn, Twitter, IgG4-related ophthalmic disease, Company, Oyster Point, Research, GLOBE, Science, Pharmaceutical industry

Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Key Points: 
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021,Oyster Point Pharma received FDAapproval for TYRVAYATM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.
  • Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them.

Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index

Retrieved on: 
Wednesday, December 15, 2021
LinkedIn, FDA, Cough, Oyster Point, Homeostasis, IgG4-related ophthalmic disease, Duane syndrome, Nach, Nasdaq, NASDAQ Biotechnology Index, Science, Sneeze, Trigeminal nerve, Research, Parasympathetic nervous system, Nose, Patient, GLOBE, Twitter, Throat irritation, NBI, Fine chemical, Pharmaceutical industry

PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Oyster Point Pharma will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20th.

Key Points: 
  • PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Oyster Point Pharma will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20th.
  • For more information about the Nasdaq Biotechnology Index,please visit here .
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021, Oyster Point Pharma received FDA approval for TYRVAYATM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

Global Diabetes Associated Ophthalmic Treatment Market Report 2021-2028: Focus on Dry Eye, Glaucoma, Diabetic Retinopathy, DAMD, Uveitis, Cataract - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021
Diabetes, Health, Optical, Patient, Adoption, Diabetes, Hospital, Awareness, WHO, Prevalence, IDF, Roy Taylor (scientist), COVID-19, Diabetic retinopathy, IgG4-related ophthalmic disease, Macular degeneration, Glaucoma, Growth, Quality of life, Pharmaceutical industry

The "Diabetes Associated Ophthalmic Treatment Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetes Associated Ophthalmic Treatment Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options.
  • COVID-19 related diabetic and ophthalmic complications are expected to boost the market for diabetes associated ophthalmic treatment methods.
  • The diabetic retinopathy segment has captured the largest revenue share in 2020 followed by diabetic associated macular degeneration and glaucoma.

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Retrieved on: 
Wednesday, December 1, 2021
Patient, Conference, Company, Nasdaq, Twitter, Research, GLOBE, IgG4-related ophthalmic disease, Oyster Point, Piper Sandler Companies, Science, LinkedIn, Duane syndrome, Pharmaceutical industry

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery,developmentand commercialization of first-in-class pharmaceutical therapies to treatophthalmicdiseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021.

Key Points: 
  • PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery,developmentand commercialization of first-in-class pharmaceutical therapies to treatophthalmicdiseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021.
  • Presentations areavailable for registered attendees via the Piper Sandler conference site
    Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • In October 2021,Oyster Point Pharma received FDAapproval for TYRVAYA(varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
  • Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations.

23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer

Retrieved on: 
Tuesday, November 30, 2021
Research, Genentech, Degenerative disease, Security (finance), 23andMe, Fellow, Chhattisgarh Special Public Security Act, Princeton University, Lijun International Pharmaceutical (Holding) Co. Ltd., Publication, Genome, IND, Autoimmunity, SEC, U.S. Securities and Exchange Commission, Laboratory, Therapy, Stanford University School of Medicine, Securities Exchange Act of 1934, IgG4-related ophthalmic disease, Genetics, GLOBE, Weill Cornell Medicine, Terminology, Sophia Hillan, National university, FDA, CA, Rockefeller University, Allergy, Asthma & Immunology Research, Cardiovascular disease, Disease, Drug discovery, Growth, Securities Act of 1933, Pharmaceutical industry

SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the companys new Chief Scientific Officer.

Key Points: 
  • SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the companys new Chief Scientific Officer.
  • We are excited to have Joe join as our Chief Scientific Officer, as he brings a proven track record of innovation in drug discovery and translational biology to 23andMe, said Hillan.
  • Dr. Arron will lead 23andMes therapeutics discovery strategy from early discovery to the IND-enabling studies stage.
  • 23andMe is trying to make this vision a reality, and I hope to help carry forward the companys mission.

Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease

Retrieved on: 
Wednesday, November 24, 2021
Patient, University of Pittsburgh School of Law, Nach, University School, Michigan, Novartis, Sneeze, Compliance, New York University School of Law, General counsel, Pennsylvania State University, Homeostasis, University, Cough, Corporation, Wilfrid Sellars, JD, IgG4-related ophthalmic disease, Nasdaq, Twitter, Research, GLOBE, Psychology, Parasympathetic nervous system, Oyster Point, LLM, Throat irritation, FDA, Science, LinkedIn, Nasal spray, Nose, Trigeminal nerve, Duane syndrome, CCEP, Pharmaceutical industry, Management

Our focus at Oyster Point Pharma is to commercialize TyrvayaTM (varenicline solution) Nasal Spray and rapidly advance our pipeline forward.

Key Points: 
  • Our focus at Oyster Point Pharma is to commercialize TyrvayaTM (varenicline solution) Nasal Spray and rapidly advance our pipeline forward.
  • We look forward to their counsel as continue to build Oyster Point into a leading company in the eye care space.
  • TYRVAYA (varenicline solution) Nasal Spray 0.03 mg (formerly referred to as OC-01 nasal spray) is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray.
  • In October 2021, Oyster Point Pharma received FDA approval for TYRVAYATM (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.

Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference

Retrieved on: 
Wednesday, November 17, 2021
Patient, Security (finance), Mucopolysaccharidosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Data analysis, Drug Quality and Security Act, Technology, Annual report, Company, Clinical trial, U.S. Securities and Exchange Commission, Bayley Scales of Infant Development, COVID-19, MPS, Securities Exchange Act of 1934, IgG4-related ophthalmic disease, Nasdaq, GLOBE, AEDT, International Congress on Tuberculosis, Neurology, Terminology, AAV, Infant, Therapy, Department, Food, Securities Act of 1933, Medical device, Pharmaceutical industry

The meeting will take place virtually and at the Hilton Sydney in Sydney, Australia on November 21-23, 2021.

Key Points: 
  • The meeting will take place virtually and at the Hilton Sydney in Sydney, Australia on November 21-23, 2021.
  • The presentation will take place during a session on Tuesday, November 23, 2021 from 11:45 am-1:15 pm Australian Eastern Daylight Time (AEDT).
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.
  • Abeonas novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 16, 2021
Securities Exchange Act of 1934, Therapy, IgG4-related ophthalmic disease, ET, Security (finance), Terminology, Technology, Food, COVID-19, Securities Act of 1933, MPS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Data analysis, Annual report, Conference, U.S. Securities and Exchange Commission, Company, GLOBE, Drug Quality and Security Act, Nasdaq, Patient, AAV, Sanfilippo, Medical device, Pharmaceutical industry

NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona, will participate virtually in a fireside chat at the Jefferies London Healthcare Conference being held November 16-19, 2021.

Key Points: 
  • NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona, will participate virtually in a fireside chat at the Jefferies London Healthcare Conference being held November 16-19, 2021.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.
  • The Companys development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.
  • Abeonas novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.